Pumu

Pulmongene (Pumu Biotechnology) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery and development of innovative therapies for respiratory, fibrotic, and autoimmune diseases. The company's lead candidate, PMG1015, is a first-in-class monoclonal antibody targeting Amphiregulin (AREG), a key driver of fibrotic processes, and has received FDA Fast Track and Orphan Drug designations for the treatment of idiopathic pulmonary fibrosis (IPF). Pulmongene leverages its deep expertise in lung biology to identify novel molecular mechanisms and translate them into transformative biologics. With a pipeline of several programs in clinical and preclinical development, the company aims to address significant unmet medical needs in chronic lung conditions and organ fibrosis.